REGENXBIO (NASDAQ:RGNX) Upgraded to "Hold" at StockNews.com

REGENXBIO (NASDAQ:RGNX - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Friday.

RGNX has been the topic of several other reports. Morgan Stanley restated an "overweight" rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Raymond James initiated coverage on REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital reissued a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Finally, The Goldman Sachs Group downgraded REGENXBIO from a "buy" rating to a "neutral" rating and cut their price target for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus target price of $33.88.

Remove Ads

REGENXBIO Stock Performance

NASDAQ:RGNX traded down $0.33 during trading hours on Friday, hitting $6.01. The company's stock had a trading volume of 607,817 shares, compared to its average volume of 940,196. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $23.57. The business's 50-day moving average is $7.44 and its two-hundred day moving average is $9.19. The company has a market capitalization of $297.77 million, a PE ratio of -1.19 and a beta of 1.35.

Institutional Investors Weigh In On REGENXBIO

Hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. lifted its stake in shares of REGENXBIO by 48.5% during the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company's stock valued at $379,000 after buying an additional 11,784 shares during the period. Sigma Planning Corp lifted its stake in shares of REGENXBIO by 17.5% during the 3rd quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company's stock worth $401,000 after purchasing an additional 5,701 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of REGENXBIO during the third quarter worth $643,000. Intech Investment Management LLC purchased a new stake in shares of REGENXBIO in the third quarter valued at $161,000. Finally, Charles Schwab Investment Management Inc. increased its stake in REGENXBIO by 9.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock valued at $4,382,000 after purchasing an additional 37,055 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.